WE BRING YOUR CANCER INTO FOCUS
How We Are Different Patient Case Studies
ctDx the Comprehensive Liquid Biopsy Platform
The ctDx platform uses next-generation sequencing (NGS) and a standard peripheral blood sample. This non-invasive assay platform has been validated to detect all
four major types of genetic alterations known to drive cancers.
Turnaround time is measured in days, not weeks.
Resolution Bioscience and LabCorp Will Collaborate to Commercialize the Resolution ctDx Lung™ Liquid Biopsy Assay
Vanderbilt Oncologists Publish Results of First Study to Demonstrate Clinical Utility of Resolution Liquid Biopsy Assay to Monitor Response and Resistance to Ensartinib
Resolution Advancing Development of Cell-Free DNA Companion Diagnostic for Prostate Cancer through Collaboration with Janssen
Resolution Liquid Biopsy Assay Demonstrates Fewer False Positives and Higher Positive Predictive Value Than Three Known Commercial ctDNA NGS Tests
Resolution Liquid Biopsy Assay Detects More Actionable Oncogenic Fusions with Higher Allele Frequency than Guardant360
Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.
ASCO GU 2019: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and Biallelic DNA-Repair Gene Defects : Preliminary Results of GALAHAD
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
Tumor evolution in real-time
Longitudinal monitoring offers the ability to monitor tumor evolution over time and under treatment. Allelic frequencies can change quickly. At disease progression, it becomes critical to have a comprehensive genotype to look for resistance mechanisms.
Patients and Clinicians
Patients are why we are here. We have all been touched by cancer. Helping patients drives us to make the best diagnostics available.
Clinicians stand at the frontline of care. As the director of patient care, we work with them to provide critical information.
Treatment starts with effective therapies. We work with biotech and pharmaceutical companies to support their clinical trials and do biomarker discovery.